REMEDi4ALL

FIP Brisbane 2023: Pharmacy building a sustainable future for healthcare – Aligning goals to 2030
2023-09-24 - 2023-09-28 | Brisbane, Australia
81ST FIP WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES
The pharmacist is key in assuring a safe and effective supply of medicines as well as their responsible use. As a direct provider of services, from primary prevention and screening of diseases, immunisations to therapeutic monitoring, the work of this profession ensures that a patient’s medical therapy is appropriate, the most effective, the safest possible and the most convenient.
The International Pharmaceutical Federation (FIP) Development Goals align pharmacists’ education with societal and healthcare needs, taking into consideration the path to universal health coverage and the UN Sustainable Development Goals, and make the case for investing in the pharmacy workforce of tomorrow.
These goals present the profession with the direction for advancement and transformation and establishing its place within the healthcare system. By linking the FIP vision with a needs-based pharmaceutical workforce transformation programme, a sustainable future for healthcare can be built — aligning goals to 2030.
Linked to a healthier world, the “Pharmacy building a sustainable future for healthcare — aligning the goals” theme sets out long-term goals and principles, as well as short-term actions, to transform the role and contribution of pharmacy. That transformation is required to maximise the health gain that healthcare systems derive from their interactions with the pharmacy profession.
Learn more and register for the congress here.

Workshop - REMEDi4ALL: what’s in it for funders?
2023-07-05 12:00 - 14:00 (Europe/Amsterdam) | Online Event
Learn and discuss how REMEDi4ALL & the funders network can support your funding activities in drug repurposing
Target audience: Funders who are (willing to be) active in drug repurposing
Within REMEDi4ALL an international funders network for drug repurposing is currently being created by ZonMw. So far, more than 50 different funders from all over the world have expressed their interest to join the network. Many of them also already shared their experiences with and ideas of funding drug repurposing with us via an online survey and in face-to-face interviews. This is the first workshop where funders who are interested in joining the funders network come together. Within an interactive setting we will talk about how REMEDi4ALL and the funders network can support funders in drug repurposing. You will learn about current and upcoming activities in REMEDi4ALL related to funders. Also, we will share and discuss the insights collected from funders on the barriers, solutions and incentives needed for funding drug repurposing.
DOWNLOAD THE EVENT SUMMARY
DOWNLOAD THE FULL PRESENTATION

Your browser does not seem to support iframes. Click here to read this PDF.
Created using FlowPaper Flipbook Maker ↗

Agenda

Time
Topic

12.00-12.05
Welcome
Chair: Heleen van der Meer (ZonMw)

12.05-12.30
Introduction REMEDi4ALL and funders network
Anton Ussi (EATRIS) & Heleen van der Meer (ZonMw)

12.30-12.40
How do you repurpose? REMEDi4ALL’s training programme for the whole repurposing ecosystem
Rick Thomson (BEACON: for rare diseases)
+ input from all participants

12.40-12.50
Introduction to the REMEDi4ALL Funding Decision Tool
Marcell Csanadi (Syreon Research Institute)
+ input from all participants

12.50-13.00
Q&A – break

13.00-13.20
Funding drug repurposing: barriers, solutions & incentives needed
Heleen van der Meer (ZonMw)

13.20-13.45
Paneldiscussion
Moderated by Pan Pantziarka (Anticancer Fund)
Panellists:

Joanna Davidge (LifeArc)
Teun Grooters (Arega Medical)
Sagair Hussain (DEBRA)
Sarah Puddicombe (National Institute for Health and Care Research Coordinating Centre (NIHR CC))

13.45-14.00
Next steps for the funders network & closing
Heleen van der Meer (ZonMw)
+ input from all participants

Creating Health Impact from Research: Course of 3 Live Sessions
2023-06-28 10:00 - 2023-07-11 12:00 (Europe/Amsterdam) | Online Event
If you are an Early Career Researcher who aims to enhance your skills to make an impact in healthcare research, this course is for perfect you!
Supported by the Wellcome Trust Institutional Translational Partnership Award (iTPA), we are working with UCL Academic Careers Office to sponsor UCL participants for this online course, with the course fee fully covered. Register now to secure your spot as there is a limited quota available on a first-come-first-served basis.
About this course
This course offers professional commercialization training for Higher Education Institutions across the UK. It consists of a series of live sessions accompanied by learning videos created by Pete Moores.
In this course, you will:

Develop an impact hypothesis for your work
Develop your route to impact skills in three live, online workshops
Get practical support through an online community

About the trainer
Pete is a consultant, mentor, coach and trainer in the translational field with a vast experience in working at the intersection of science and technology, industry application and funding. He’s driven by a passion to create real-world benefits from new science and technology.
He has previously worked as a head coach on international training and mentoring programmes and has mentored, coached, and trained global researchers and entrepreneurs to develop strategic sales and marketing initiatives that unlock their innovation potential.

Live Session Programme

Wednesday 28 June 2023, 10:00-12:00
Building a Bridge to the Market: the foundations of commercialisation
Wednesday 5 July 2023, 10:00-12:00
How to Write a Successful Translational Research Application
Tuesday 11 July 2023, 10:00-12:00
Creating impact from scientific research

Who is this course for?
We encourage Early Career Researchers (e.g. post-docs, fellows and newly established lecturers) with an interest in delivering impact in healthcare research to sign up, but this course is also open to any researcher who has not previously had translational-type project funding independent of their career stage. This course is NOT suitable for PhD or MRes students. If you have not engaged in any previous translational activity, but are keen to do so, this is the course for you!

Course Delivery
This workshop has been arranged by the University of Birmingham Translational Research Team, together with a network of other Universities, each supported by a Wellcome Trust Institutional Translational Partnership Award (iTPA). This event is part of an ongoing effort to support researchers in translating ground-breaking discovery research findings into practical improvements in human health.
UCL participants will join the training sessions alongside researchers from the University of Birmingham, and everyone will be encouraged to ask questions and network with fellow attendees.

Learn more and register here.

Open Academy Schools 2023
2023-06-19 - 2023-06-23 | Barcelona
The Open Academy School on Medicines Research & Development is a training programme offered by
EURORDIS, designed to help participants become experts in medicines research and development.
The 2023 edition of the Open Academy Schools will take place in-person from 19-23 June in Barcelona. Schools are delivered in English in a blended format, comprising e-learning modules, pre-training webinars and face-to-face intensive days. Following a review of our training offerings, we are excited to announce a new format for our in-person training.
From 2023, the face-to-face intensive week of the Open Academy School on Medicines Research & Development (formerly EURORDIS Summer School) and the Open Academy School on Scientific Innovation & Translational Research (formerly EURORDIS Winter School) will take place during the same week, incorporating three days of parallel sessions and two days of joint sessions focusing on patient engagement across the whole life-cycle of a medicine. Greater knowledge sharing and networking opportunities will be fostered with both sets of trainees together during the week.
The new format will include off-site visits to research facilities, greater contact time with faculty and EURORDIS staff and the chance to network with fellow patient advocates, supporting each other in learning and practice during the training and beyond.
Click here to learn more and to submit your application. The deadline for sending applications is on October 24.

Personalized Health Series - Workshop on Drug Repurposing
2023-05-12 13:30 - 18:15 (Europe/Amsterdam) | Innovation Office Garage, Kreuzstrasse 4, Allschwil
The goal of this workshop series is to foster and strengthen partnerships and collaborations between industry and universities, and to define a few pilot projects that are leading to innovation and societal impact.
This year’s edition will focus on Drug Repurposing. As in previous workshops, the goal is to engage professionals from both academia and the pharma sector, showing their joint initiatives with the aim to inspire new potential partnerships, and to spark interdisciplinary and cross-functional interests.
The presentation of these join initiatives will be followed by the panel discussion “Harnessing the power of collaborations and partnerships”, which will explore how to facilitate and accelerate partnerships and collaborations between academia and industry, as well as how to remove obstacles to pave the way into impactful progess.
AGENDA
13:30 – 13:45 Welcome

Dr. Bram Stieltjes, Head of Department Research & Analysis Services, University Hospital
Basel, Chair of Personalized Health Basel
Dr. Raffaello Ferone, Research Coordinator at Personalized Health Basel
Dr. Alessandro Mazzetti, Team Lead, Innovation Collaborations at Innovation Office

Collaborations between Pharma companies and Academia
13:45 – 14:10 Genome-assisted drug repurposing in psychiatry

Prof. Andreas Papassotiropulos, University of Basel

14:10 – 14:35 Combining Protein & Ligand Centric approaches to predict Drug Repurposing with in-silico
Polypharmacology

Dr. Andrea Beccari, Dompé farmaceutici S.p.A.

14:35 – 15:00 REMEDi4ALL – the European platform for medicines repurposing & REMEDi4ALL Funders Network

Dr. Heleen van der Meer, ZonMw, and Dr. Anton Ussi, EATRIS

15:00 – 15:20 Break
15:20 – 15:50 Pitching session

Small Molecules, Big Opportunities: A Multi-Purpose Platform for Off-Target Analysis
Prof. Martin Smiesko, University of Basel
Using implementation science to power the research pipeline towards faster transla-
tion in real-world settings
Dr. Sabine Valenta, Institute for Nursing Science
Holistic Approach to Personalized Medicine & Host-Response Monitoring: Quantifying Pro-
tein & Nucleic Acid Biomarkers with Diaxxo’s Desktop qPCR Platform
Engr. Joseph Iwasyk, Swiss TPH
Drug repurposing for helminth infections
Prof. Jennifer Keiser, Swiss TPH
Picky Binders: choose the right predictor for your drug or target
Dr. Janani Durairaj, University of Basel

15:50 – 17:10 Panel discussion: Harnessing the power of collaborations and partnerships: What is still needed in Drug Repurposing? From in-silico discoveries to business models – How to
remove obstacles and facilitate and accelerate partnerships and collaborations?
Panelists: Prof. Henriette Meyer zu Schwabedissen (University of Basel), Charlotte Piens
(STADA Arzneimittel AG), Dr. Andrea Beccari, (Dompé farmaceutici S.p.A.), Engr. Silvano
Coletti (CEO Chelonia Applied Science) Moderator: Dr. Benjamin Kasenda (Senior Consul-
tant Medical Oncologist, University Hospital Basel)
17:10 – 18:15 Networking Apéro

Organising Team:

Raffaello Ferone (Personalized Health Basel) – raffaello.ferone@unibas.ch
Alessandro Mazzetti (Innovation Office) – alessandro.mazzetti@unibas.ch

DIA Europe 2023
2023-03-22 - 2023-03-24 | Basel, Switzerland
DIA EUROPE is the largest neutral event in the European life science industry – the knowledge hub between science, healthcare, and regulation. For it’s 35th anniversary, DIA Europe is back in Basel, where all thought leaders meet in person to discuss, inspire, and network.
DIA Europe 2023 is designed to drive insights into action by connecting key policy discussions to real-world knowledge. Gathering innovative thought leaders from the entire life science landscape, DIA will have 4 new content tracks in 2023:

Artificial Intelligence and Data Science
EU Health Policy and Regulatory Strategy
Medical Devices and Combination Products
Professional Development

Learn more about DIA EUROPE 2023 here.

Rare Disease Day 2023
2023-02-28
Rare Disease Day – observed on the last day of February – aims to raise awareness for those living with a rare disease and their families and carers, as well as help improve therapeutic options and access to treatments.
About 3.5-5.9% of the world population (around 260-440 million people) is living with a rare disease. Those affected with a rare disease face specific challenges. Initial misdiagnosis and delay in diagnosis are common due to lack of scientific knowledge and varying symptoms between patients with the same rare disease. Additionally, those living with a rare disease face difficulties in accessing quality treatments and care.
REMEDi4ALL pursues the exploration of using existing medicines to address areas of unmet medical needs, including the research of innovative repurposed medicines for targeted rare diseases.

3rd PSTC Japan Safety Biomarker Workshop
2023-02-20 10:00 - 18:30 (Asia/Tokyo) | Fujisawa, Japan, SHONAN HEALTH INNOVATION PARK 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
C-Path’s Predictive Safety Testing Consortium will be hosting its 3rd PSTC Japan Safety Biomarker Workshop on February 20, 2023 in Fujisawa, Japan.
The utilization of biomarkers in guiding drug development decisions through clinical trials and post marketing studies is increasing. This conference will explore the areas of cooperation in the clinical application of biomarkers and drug development tools and their qualification and share knowledge about safety biomarkers in drug development via speaker presentations and panel discussions. Representatives from academia, government and industry will participate. The workshop is co-sponsored by The Japan Society of Toxicology.
Learn more and register for the workshop here.

Webinar: Getting Started with Medicines Repurposing
2023-02-08 14:00 - 15:30 (Europe/Amsterdam)
BEACON has partnered with LifeArc to help patient group leaders and academics team up to begin repurposing research on their specific rare condition.
Join us for a 3-part educational series that progresses through the drug repurposing journey using LifeArc’s newly developed Drug Repurposing toolkit that’s been designed with patient groups and academics in mind!
It takes a village to bring a licensed treatment to market, especially when developing it from scratch. Drug repurposing provides hope.
Register now to learn how to navigate the drug repurposing landscape and bring a repurposed therapy to market!
Dates of 3-part educational series: 8th February, 22nd February, 8th March
Please note: This educational series is for leaders of rare disease patient groups and those within them that have a medical/scientific interest in drug development and repurposing. Academics who are thinking of getting involved in rare repurposing and research are highly encouraged to attend this series, as it’s been designed specifically to benefit you!

Critical Path to Women Leading in Science
2023-02-06 19:30 - 21:00 (Europe/Amsterdam) | Online Event
On February 6, C-Path is going to host a 90-minute roundtable discussing the Critical Path Institute’s programs and consortia, highlighted by various women leaders at this public-private partnership. The team will discuss how C-Path contributes to transforming and accelerating the medical product development process, as well as their personal professional development journey. The roundtable will include an interactive Q&A session, where the audience can ask specific questions about C-Path activities and, more generally, scientific career paths.
Learn more and register here.

Informed and Shared Decision-Making Webinar
2023-01-18 16:00 - 18:00 (Europe/Amsterdam) | Online Event
Health literacy, patient empowerment, shared decision-making and patient involvement are no buzzwords, but major cornerstones of a successful, efficient and effective patient-centred healthcare. All patients have the right to receive accurate information about their cancer, their different treatment options and the potential side effects.
The Anticancer Fund has been involved in the cancer literacy-topic within the Inequalities Network of the European Cancer Organisation. Both organisations worked on a paper recently published in the Journal of Cancer Policy: “Cancer literacy – Informing patients and implementing shared decision making”. The article highlights the importance of health literacy to empower patients in their journey through treatment and gives several recommendations for improving cancer literacy in Europe.
Building on this paper, the Anticancer Fund and the European Cancer Organisation are co-hosting a webinar gathering cancer patients, caregivers, healthcare professionals and policymakers. Participants will be sharing their perspective on ‘Well-informed and shared decision-making in oncology – why is it important and how can we make it happen?” The event aims to illustrate to key policy- and decision-makers, the value and benefit of reliable information when it comes to taking real steps in bettering cancer care.
The webinar will be co-chaired by Kathy Oliver, Chair and founding Co-Director of the International Brain Tumour Alliance (IBTA) – Co-Chair, E.C.O. Patient Advisory Committee, and Guy Buyens, Medical Director, Anticancer Fund – Contributor to E.C.O.’s Community 365.
Learn more about the webinar and register as an attendee here.

VALUE ADDED MEDICINES CONFERENCE #VAM22
2022-11-30 | Thon Hotel Eu, Brussels, Rue d'Arlon 81, Brussels, Belgium
The 4th Value Added Medicines Conference – #VAM22 – takes place on 30 November 2022 in Brussels (Belgium). The theme this year is “Giving medicines a new life”.
Value Added Medicines (VAMs) present an opportunity to bring treatments for indications with no approved therapies and improve existing ones. They can reduce unmet medical need (repurposing/repositioning), optimise existing medicines to allow for patient-centric design or address healthcare inefficiencies (reformulation) and combine medicines or substances with digital services or devices to substantially improve treatment outcomes (complex combinations).
In Europe, there is significant untapped potential in innovation on existing therapies, providing an opportunity for patients, healthcare providers, payers, industry and healthcare systems. Re-evaluating the current innovation model should lead to greater focus on ways to stimulate innovation across the lifecycle of medicines and especially on off-patent molecules.
To promote an innovation ecosystem that focuses on relevant benefits to society, we need to consider some fundamental changes in the way innovation is currently fostered and evaluated. The pharmaceutical industry is transforming to continuously bring value to patients through sustained innovation in off-patent medicines.

How can VAMs address some of the key healthcare challenges of today?
How can the value of VAMs be captured for society?
How are we advancing medicine repurposing in Europe?
How could we shape an EU environment that supports continuous treatment improvements? How does continuous innovation fit into the broader EU agenda to bolster access to treatment and innovation?

The Value Added Medicines Conference will gather a wide range of experts in the healthcare community to share best practices and discuss patient access to continuous innovation. Come and join us to learn more about Value Added Medicines and to discuss the current environment, challenges, and opportunities in Europe.

Broad-spectrum anti-viral therapeutics: A key tool for pandemic preparedness
2022-11-22 - 2022-11-23 | The Comet Louise Place Stéphanie 20, Brussels, Belgium
The workshop “Broad-spectrum anti-viral therapeutics: A key tool for pandemic preparedness” is going to take place on 22 and 23 November 2022 in Brussels, Belgium.
The workshop will be focusing on the following aspects:

Broad-spectrum antivirals in pandemic preparedness & response
COVID-19 and pandemic preparedness
Pre-clinical research of broad-spectrum antivirals
Clinical research environment
Availability & Access
Global context

This high-level workshop is organized by “VO Communication” and the European Commission.
You can find the detailed workshop agenda here, as well as the background scoping paper here.

World Orphan Drug Congress Europe 2022
2022-11-14 - 2022-11-17 | MELIA SITGES HOTEL, Sitges, Barcelona, Spain
STRATEGY, ADVOCACY & PARTNERING FOR THE GLOBAL ORPHAN DRUG INDUSTRY
The World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.
Now in its 13th annual edition, the World Orphan Drug Congress Europe, together with the co-located Cell & Gene Therapy Congress, will continue to bring experts from the whole value chain under one roof, where you get to meet decision makers in the areas that are most applicable for your business offering.
Three REMEDi4ALL partners will be joining the congress as speakers. On the afternoon of 16 November, Anton Ussi (Operations & Finance Director for EATRIS ERIC) will be taking part in the panel discussion “Together4RD – Multi-stakeholder initiative to unlock ERN collaboration with industry”. Additionally, on the morning of 17 November, Eva Molero (Chief Executive Officer at Teamit Research) and Rick Thompson (Chief Executive Officer at Beacon) will be participating in the panel discussion “The evolving world of drug repurposing”.
Click here to see the full agenda. Register for the event here.

Drug Repositioning and Repurposing Conference
2022-11-14 - 2022-11-15 | Westin Arlington Gateway, 801 North Glebe Road, Arlington, VA, 22203, United States
Join us at the 10TH ANNUAL DRUG REPOSITIONING AND REPURPOSING CONFERENCE, where attendees will meet and learn from the world’s foremost experts in the fields of repositioning and repurposing. As the Single Longest-Running Conference in the Space, Arrowhead Publishers’ annual event continues to be the “go to” meeting for pharma executives, academicians, researchers and patient advocacy groups who want to keep abreast of new developments in the field, learn from experts and meet possible collaborators and partners.
Key Subjects Covered at This Event
Patient Advocacy Efforts
Emphasis on and engagement with patient advocacy groups, who are investing in drug repositioning efforts to an unprecedented degree.
New Partnerships
The conference will explore how new partnerships between various groups, including government, industry and academia are advancing repurposing.
Systematic Repositioning & Data Analytics
Repurposing is no longer based on serendipity as more and more companies are designing tools to streamline and increase the odds of success.
Cutting-Edge Technologies
Artificial intelligence and other technologies are quickly reshaping drug discovery and development. This event will showcase how they are reshaping the field of drug repurposing.
Regulatory and Legal Guidance
Legal, IP and regulatory guidance will be shared with the audience, including knowlege and insight into the 505(b)(2) regulatory pathway.
Key Therapeutic Areas for Repurposing
Repurposing is beginning to make its mark in a range of therapeutic areas in need of new therapies. Rare and orphan diseases, tropical diseases and cancer will be discussed in terms of repurposing efforts currently underway.

Advanced Course in Network Medicine
2022-10-19 12:00 - 2022-10-20 12:30 (Europe/Amsterdam) | Campus Flemingsberg & Online
KI NMA is proud to invite you to participate in an advanced course in Network medicine – “From byte to bench to bed side – addressing large and complex data sets in biomedicine”.

The advanced course in network medicine “From byte to bench to bed side – addressing large and complex data sets in biomedicine” will be held both at Neo (Campus Flemingsberg) and streamed online.

The course is aimed towards PhD students, postdocs, researchers and everyone else that wants to learn more about the topic of network medicine, its application and implementation.
The course will start with a key note speaker, Professor Ed Silverman, Channing Division of Network Medicine, Brigham and Wome’s Hopital/Harvard Medical School, and the following session of the course will see lecture given by distinguished scientist from Europe and Sweden. The sessions will be followed by panel debates on the pros and cons, and the innovative potential of Network Medicine.
Updated program. Registration is now closed.

Drug Repurposing for Rare Diseases 2022
2022-10-10 09:00 - 18:00 (Europe/London) | America Square Conference Centre, 17, One Crosswall, America Square, Londen, EC3N 2LB, United Kingdom
We are delighted to announce our ninth annual Drug Repurposing for Rare Diseases Conference and, for the first time since 2020, it’s returning live and in-person!
Our annual conference, Drug Repurposing for Rare Diseases, highlights the role that drug repurposing can play in lowering the cost and accelerating the development of rare disease treatments.
An event unique in its collaborative and multi-stakeholder focus, we bring patient groups, researchers and industry professionals together to showcase excellent examples of rare repurposing.
Drug Repurposing for Rare Diseases sparks cross-sector conversation, uniting the expertise of diverse groups to inspire meaningful, patient-centred drug repurposing research for rare diseases.

CeBIL Annual Symposium 2022 - Intellectual Property and Drug Repurposing: New Frontiers
2022-09-16 00:00 - 18:00 (Europe/London) | Newnham College, University of Cambridge, Sidgwick Avenue, Cambridge, CB3 9DF, United Kingdom
Repurposing, the idea of finding new treatments for already authorised drugs, presents significant advantages for drug development. Modern drug development is hindered by high costs and research that takes over a decade.
Repurposing is a potential solution to these problems because it is cheaper, faster and safer than developing new compounds. However, academics, policymakers and industry experts argue that repurposing is underutilised, pointing at gaps in patent and pharmaceutical law that make it financially unviable.
The symposium will focus on important policy issues for pharmaceutical repurposing. In particular, it will examine new empirical data on patent protection, regulatory exclusivities and market authorisation pathways. It will also discuss two new public sector repurposing initiatives launched in the UK and EU, and investigate other policy frontiers. It will have a hybrid format, with both in-person and online only tickets available.
The 2022 CeBIL Symposium is organised by the Cambridge Centre for Law, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen. The Symposium is generously supported by the Novo Nordisk Foundation.
Hosted by the University of Cambridge, an international hub for legal and scientific expertise, we hope the event will stimulate discussion between legal, economic,business, medical, and scientific experts at a range of career stages.
Confirmed participants include:

Prof. Timo Minssen (CeBIL, University of Copenhagen)
Prof. Kathleen Liddell (LML, University of Cambridge)
Prof. Mateo Aboy (LML, University of Cambridge)
Dr Jakob Wested (CeBIL, University of Copenhagen & Danish Medicines Agency)
Ms Eugenia Wachters (Healx)
Dr Anita Marguerie de Rotrou (Office for Translational Research, University of Cambridge)
Mr Adrian Freeman (AstraZeneca)
Professor Ken Shadlen (London School of Economics)
Dr John Liddicoat (LML, University of Cambridge)
Dr Rosemary Lovett (Medicines Repurposing Programme, NHS England)
Dr Charlotte Asker-Hagelberg (Swedish Medical Products Agency)
Dr Julian Huppert (Intellectual Forum, Jesus College, University of Cambridge)
Dr Marco Schito (Critical Path Institute)
Mr Paul Fleming (British Generic Manufacturers Association)
Ms Jacqueline Mulryne (Arnold & Porter)
Prof. Sir Munir Pirmohamed (NHS Chair of Pharmacogenetics & University of Liverpool)

The CeBIL Symposium will coincide with the EPIP Annual Conference in Cambridge (14-16 September 2022).

REXPO22 – 1st international conference on drug repurposing
2022-09-02 08:00 - 2022-09-03 17:00 (Europe/Amsterdam) | The Function Hall, Maastricht, 6229 EP, Netherlands
The REPO4EU Horizon Europe project to build a European/Global Platform for Drug Repurposing will kick off with the 1st International Conference on Drug Repurposing.
RExPO22 is the first instalment in the RExPO annual conference series and will take place in Maastricht, the Netherlands.
REPO4EU and RExPO22 have partnered with professional societies, companies, patent attorneys, legal and ethics experts, clinical research organisations, regulators, payers, patient representatives and many more! We have multiple collaborations around the world that pool together their knowledge and know-how to deliver the best possible outcome in the single major opportunity in drug development, i.e drug repurposing.
The speakers include Anton Ussi, EATRIS Operations and Finance Director, who will also co-chair the conference.
Find out more and see the agenda here. Abstract submission is still open here.
